Get the Stockscreener App
106.50
0.43%
-0.4801
Novartis Ag Adr stock is traded at $106.50, with a volume of 590.27K.
It is down -0.43% in the last 24 hours and up +7.61% over the past month.
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
See More
Previous Close:
$106.98
Open:
$107.35
24h Volume:
590.27K
Relative Volume:
0.42
Market Cap:
$211.30B
Revenue:
$51.72B
Net Income/Loss:
$11.94B
P/E Ratio:
18.11
EPS:
5.88
Net Cash Flow:
$13.81B
1W Performance:
+1.71%
1M Performance:
+7.61%
6M Performance:
-4.18%
1Y Performance:
+2.95%
1-Day Range:
$106.38
$107.37
1-Week Range:
$104.07
$110.08
52-Week Range:
$92.35
$120.92
Novartis Ag Adr Stock (NVS) Company Profile
Name
Novartis Ag Adr
Sector
Industry
Phone
-
Address
-
Compare NVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
106.50 | 211.30B | 51.72B | 11.94B | 13.81B | 5.88 |
|
LLY
Lilly Eli Co
|
881.00 | 827.20B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
86.38 | 386.95B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
JNJ
Johnson Johnson
|
153.75 | 344.63B | 88.82B | 14.07B | 19.03B | 5.79 |
|
ABBV
Abbvie Inc
|
192.16 | 341.01B | 56.33B | 4.28B | 15.62B | 2.40 |
|
MRK
Merck Co Inc
|
87.95 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Dec-04-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Sep-11-24 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-05-24 | Downgrade | Goldman | Buy → Neutral |
| Sep-03-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-24 | Downgrade | Deutsche Bank | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-23-24 | Initiated | BMO Capital Markets | Market Perform |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-25-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-26-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-27-23 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-26-23 | Downgrade | Citigroup | Buy → Neutral |
| Dec-05-22 | Upgrade | Stifel | Hold → Buy |
| Sep-15-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| May-09-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-10-22 | Resumed | Citigroup | Buy |
| Dec-14-21 | Downgrade | Redburn | Buy → Neutral |
| Dec-06-21 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Dec-03-21 | Downgrade | Bryan Garnier | Buy → Neutral |
| Sep-20-21 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-22-21 | Initiated | Bernstein | Mkt Perform |
| Mar-10-21 | Downgrade | Argus | Buy → Hold |
| Feb-01-21 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Sep-10-20 | Upgrade | UBS | Neutral → Buy |
| Sep-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-15-20 | Upgrade | Citigroup | Neutral → Buy |
| Mar-10-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-25-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-25-19 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-10-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-02-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-11-18 | Resumed | Jefferies | Buy |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Sep-10-18 | Upgrade | BofA/Merrill | Underperform → Buy |
| May-29-18 | Downgrade | HSBC Securities | Buy → Hold |
| May-25-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jan-25-18 | Reiterated | Leerink Partners | Outperform |
| Dec-06-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jul-26-17 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jul-05-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Mar-09-17 | Initiated | Liberum | Buy |
View All
Novartis Ag Adr Stock (NVS) Latest News
NVS’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Novartis AG ADR (NVS) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Novartis AG ADR [NVS] is 12.85% higher this YTD. Is it still time to buy? - The DBT News
Delhi High Court grants ad interim injunction to leading pharmaceutical company NOVARTIS; restrains use of NOVITAS mark - SCC Online
Aplastic Anemia Global Clinical Trials Review 2024 | Now Available - GlobeNewswire Inc.
HSBC Securities downgrades Novartis AG ADR (NVS) rating to a Reduce - Knox Daily
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond - sharewise
Novartis Posts Q4 Earnings And Sales Beat, Shares Gain - Barchart
Novartis at ASH - Novartis
Novartis Financial Results – Q1 2023 - Novartis
Novartis ADR earnings beat by $0.16, revenue topped estimates - Investing.com South Africa
J.P. Morgan Healthcare Conference 2024 - Novartis
Novartis Financial Results – Q2 2024 - Novartis
Building belonging - Novartis
Novartis in Society Integrated Report 2024 - Novartis
Novartis to Report Q4 Earnings: What's in the Offing? - Yahoo Finance
AI Pharma: 2 Paths to AI-Powered Drug Investment - sharewise
Inari Medical Inc (NASDAQ: NARI): Getting A Free Pass? - Stocks Register
Metrics That Matter About Deutsche Bank AG (NYSE: DB) - Stocks Register
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
Saudi Arabia Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
South Korea Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
Thailand Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
Japan Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
The United States Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
The UAE Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
Canada Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
Weekly Upgrades and Downgrades - InvestorPlace
RAPT Therapeutics sees 113% spike on allergy med licensing deal & private placement - Mugglehead
Communiqué de presse - GlobeNewswire Inc.
Are Investors Undervaluing Novartis (NVS) Right Now? - Yahoo Finance
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement for PLUVICTO™ - Barchart
Novartis: Time To Increase (NYSE:NVS) - Seeking Alpha
Glaucoma Therapeutics Strategic Industry Report 2024 - GlobeNewswire Inc.
5 high-yielding stocks that best reflect the UN’s Sustainable Development Goals - Equities News
Novartis Canada awards more than $680,000 to community-based programs aimed at advancing health equity - Barchart
5 High-Yielding Stocks Addressing the U.N. Sustainable Development Goals - Morningstar
Novartis Raises Sales Outlook For Mid-Term, Acquires Kate Therapeutics - Barchart
Novartis Ag Adr Stock (NVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.01%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):